CRYO CELL INTERNATIONAL INC CCEL

Healthcare SIC 8090 - Services-Misc Health & Allied Services, NEC NAICS Health Care and Social Assistance › Ambulatory Health Care Services › Outpatient Care Centers › Other Outpatient Care Centers › Kidney Dialysis Centers derived NYSE

Cryo-Cell International, Inc. (the "Company" or "Cryo-Cell") is a Delaware corporation that was incorporated in 1989. The Company is organized in three reportable segments; 1.) cellular processing and cryogenic storage for family use, with a current focus on the collection and preservation of umbilical cord blood and tissue stem cells, 2.) the manufacture of PrepaCyte® CB Processing System ("PrepaCyte CB") units, the processing technology used to process umbilical cord blood stem cells, and 3.) cellular processing and cryogenic storage of umbilical cord blood stem cells for public use. The Company, in combination with its global affiliates, currently stores over 250,000 cord blood and cord tissue specimens worldwide for the exclusive benefit of newborn babies and possibly other members of their families. Founded in 1989, the Company was the world's first private cord blood bank to separate and store stem cells in 1992. The Company's U.S.-based business operations, including the processing and storage of specimens, are handled from its headquarters facility in Oldsmar, Florida. The specimens are primarily stored in commercially available cryogenic storage units at the Company's technologically and operationally advanced facility in Durham, NC.

Last close 4.46 2026-10-23
Market cap $35.9M 2026-05-31 share count
52-week range 2.72 - 4.90

Valuation FY2025 figures against the last close

P/S1.1x
P/E—
P/FCF6.8x
EV/EBITDA27.9x
Dividend yield9.0%
Diluted EPS-0.30

Annual financial statements

Income statement

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue $31.6M$32.0M$31.3M$30.3M$28.9M$31.1M$31.8M$29.2M$25.4M$23.1M
Cost of revenue $7.4M$7.9M$8.4M$8.8M$9.0M$9.7M$10.0M$8.5M$6.7M$5.8M
Gross profit $24.2M$24.0M$23.0M$21.5M$19.9M$21.5M$21.8M$20.7M$18.7M$17.4M
R&D $376.3K$1.2M$1.2M$384.8K$49.9K$23.9K$30.1K$91.8K$41.2K$53.1K
SG&A $18.2M$18.5M$17.2M$15.6M$14.6M$14.3M$14.9M$15.6M$13.5M$14.7M
Total operating expenses $31.1M$28.5M$43.6M$26.3M$24.9M$23.5M$26.8M$24.0M$20.4M$22.7M
Operating income $482.4K$3.5M-$12.3M$4.0M$4.0M$7.7M$5.1M$5.2M$5.0M$433.6K
Interest expense $2.1M$1.9M$1.2M$1.5M$1.4M$1.5M$1.7M$1.5M$1.3M$947.3K
Pre-tax income -$2.3M$2.8M-$13.4M$3.3M$2.6M$5.0M$3.4M$3.6M$3.6M-$2.5M
Income tax $92.2K$2.4M$3.8M$547.5K$527.7K$1.4M$1.1M$4.5M$1.3M$1.2M
Net income -$2.4M$402.1K-$9.5M$2.8M$2.1M$3.6M$2.3M-$854.8K$2.3M-$1.3M
EPS, basic -0.300.05-1.140.330.260.480.29-0.110.33-0.16
EPS, diluted -0.300.05-1.140.330.250.450.27-0.110.30-0.16
Shares, diluted (wtd. avg.) 8.1M8.2M8.3M8.5M8.4M8.1M8.4M7.5M7.7M8.1M

Balance sheet

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents $319.0K$561.0K$406.1K$1.7M$8.3M$10.4M$6.5M$6.0M$6.3M$3.5M
Short-term investments $3.0M$2.9M$574.2K$17.6K$75.4K$88.5K$904.1K$875.7K$439.3K$624.2K
Receivables $6.8M$7.3M$6.6M$6.0M$5.3M$6.3M$6.1M$5.9M$5.1M$4.1M
Inventory $408.8K$657.7K$768.9K$851.2K$921.2K$927.3K$1.1M$1.3M$314.6K$361.1K
Total current assets $11.8M$12.6M$9.5M$9.6M$15.8M$18.6M$15.4M$14.8M$12.7M$9.0M
Property, plant and equipment $21.0M$21.9M$21.0M$13.6M$3.2M$1.6M$1.8M$1.5M$882.4K$979.5K
Goodwill $1.9M$1.9M$1.9M$1.9M$1.9M$1.9M$1.9M$1.9M$0$0
Other intangibles $863.1K$921.3K$989.1K$1.5M$1.6M$1.2M$1.2M$1.3M$226.4K$261.0K
Total assets $61.7M$64.7M$61.2M$64.9M$60.7M$46.2M$42.9M$42.4M$23.9M$19.5M
Accounts payable $2.9M$1.9M$3.2M$1.6M$1.5M$957.4K$1.4M$1.3M$1.9M$1.5M
Total current liabilities $19.8M$21.6M$20.9M$19.5M$21.1M$16.4M$15.4M$15.4M$13.9M$13.1M
Long-term debt $8.4M$8.5M$8.6M$8.7M$1.9M$5.9M$9.0M$12.9M$1.4M$1.4M
Total liabilities $80.3M$77.9M$72.3M$66.4M$56.5M$48.9M$49.8M$51.3M$36.4M$35.0M
Retained earnings -$38.4M-$32.8M-$31.2M-$21.6M-$16.7M-$18.8M-$22.4M-$25.3M-$24.5M-$26.8M
Total equity -$18.6M-$13.2M-$11.0M-$1.5M$4.2M-$2.7M-$7.0M-$8.9M-$12.5M-$15.4M

Cash flow

Fiscal year FY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Operating cash flow $5.5M$6.0M$8.9M$8.6M$7.9M$8.5M$6.3M$5.3M$5.7M$5.0M
Depreciation and amortisation $985.2K$693.8K$1.4M$1.5M$1.0M$372.3K$401.3K$317.3K$230.0K$243.0K
Stock-based compensation $417.1K$781.1K$816.6K$461.3K$301.6K$622.1K$397.8K$478.4K$971.7K$1.8M
Capital expenditure $230.5K$2.4M$6.8M$12.2M$1.8M$100.0K$662.3K$446.2K$98.3K$343.0K
Investing cash flow -$975.3K-$4.9M-$8.1M-$15.3M-$7.0M$357.5K-$662.3K-$11.3M$93.0K-$369.7K
Financing cash flow -$4.7M-$979.1K-$2.1M$147.9K-$3.1M-$5.0M-$5.1M$5.7M-$3.0M-$5.3M
Dividends paid $3.2M$2.0M$0$7.7M$0—————
Buybacks $169.5K$1.4M$799.0K$1.8M$249.4K—$992.2K—$446.6K$10.8M

Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-083096.

Plot the figures US dollars

Income statement Revenue Cost of revenue Gross profit R&D SG&A Total operating expenses Operating income Interest expense Pre-tax income Income tax Net income EPS, basic EPS, diluted Shares, diluted (wtd. avg.)
Balance sheet Cash and equivalents Short-term investments Receivables Inventory Total current assets Property, plant and equipment Goodwill Other intangibles Total assets Accounts payable Short-term debt Total current liabilities Long-term debt Total liabilities Retained earnings Total equity
Cash flow Operating cash flow Depreciation and amortisation Stock-based compensation Capital expenditure Investing cash flow Financing cash flow Dividends paid Buybacks
  • Revenue
  • Gross profit
  • Net income
Revenue, Gross profit, Net income by fiscal year, in US dollars The same figures are in the table below this chart. -20M 0 20M 40M Revenue, FY2016: 23.1M Gross profit, FY2016: 17.4M Net income, FY2016: -1.3M Revenue, FY2017: 25.4M Gross profit, FY2017: 18.7M Net income, FY2017: 2.3M Revenue, FY2018: 29.2M Gross profit, FY2018: 20.7M Net income, FY2018: -854.8K Revenue, FY2019: 31.8M Gross profit, FY2019: 21.8M Net income, FY2019: 2.3M Revenue, FY2020: 31.1M Gross profit, FY2020: 21.5M Net income, FY2020: 3.6M Revenue, FY2021: 28.9M Gross profit, FY2021: 19.9M Net income, FY2021: 2.1M Revenue, FY2022: 30.3M Gross profit, FY2022: 21.5M Net income, FY2022: 2.8M Revenue, FY2023: 31.3M Gross profit, FY2023: 23M Net income, FY2023: -9.5M Revenue, FY2024: 32M Gross profit, FY2024: 24M Net income, FY2024: 402.1K Revenue, FY2025: 31.6M Gross profit, FY2025: 24.2M Net income, FY2025: -2.4M FY2016 FY2017 FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 FY2025
Fiscal year FY2016FY2017FY2018FY2019FY2020FY2021FY2022FY2023FY2024FY2025
Revenue $23.1M $25.4M $29.2M $31.8M $31.1M $28.9M $30.3M $31.3M $32.0M $31.6M
Gross profit $17.4M $18.7M $20.7M $21.8M $21.5M $19.9M $21.5M $23.0M $24.0M $24.2M
Net income -$1.3M $2.3M -$854.8K $2.3M $3.6M $2.1M $2.8M -$9.5M $402.1K -$2.4M

Recent filings and events

  • Delisting notice The exchange has told the company it no longer meets the rules for staying listed - usually price, market cap, or filings that are late. Item 3.01
  • Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
  • Delisting notice Item 3.01
  • Regulation FD disclosure Item 7.01
  • Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
  • Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
  • Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
  • New debt or obligation The company has taken on debt or a comparable obligation. Item 2.03
  • Other event Item 8.01
  • Material agreement terminated An agreement that mattered has ended. Often the other half of a deal that fell through. Item 1.02
  • Other event Item 8.01
  • Annual report filed Form 10-K

Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.

Others in SIC 8090

TickerCompanyMarket capP/ERevenue growth
DVA DAVITA INC. $11.72B 18.7x 6.5%
SHC Sotera Health Co $5.17B 67.0x 5.7%
PGNY Progyny, Inc. $2.22B 44.6x 10.4%
AGL agilon health, inc. $1.51B — -2.1%
VMD VIEMED HEALTHCARE, INC. $373.3M 26.5x 20.5%
BRTX BioRestorative Therapies, Inc. $41.3M — -10.3%
MGRX MANGOCEUTICALS, INC. $5.0M — -26.0%
FMS Fresenius Medical Care AG — — —